Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Acquired by Federated Hermes Inc.

Federated Hermes Inc. grew its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 1,233,875.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 49,359 shares of the biotechnology company's stock after acquiring an additional 49,355 shares during the quarter. Federated Hermes Inc.'s holdings in Aurinia Pharmaceuticals were worth $443,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of AUPH. State Street Corp increased its holdings in Aurinia Pharmaceuticals by 2.3% in the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company's stock valued at $21,587,000 after purchasing an additional 64,949 shares in the last quarter. Barclays PLC lifted its position in Aurinia Pharmaceuticals by 187.6% during the 3rd quarter. Barclays PLC now owns 219,331 shares of the biotechnology company's stock worth $1,607,000 after acquiring an additional 143,072 shares in the last quarter. Blue Trust Inc. boosted its holdings in Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 6,174 shares during the period. Atria Wealth Solutions Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $135,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth $9,662,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.

Aurinia Pharmaceuticals Stock Up 4.2 %

AUPH traded up $0.33 during trading on Wednesday, hitting $8.22. The company had a trading volume of 450,985 shares, compared to its average volume of 1,413,057. The company has a market cap of $1.13 billion, a PE ratio of -54.80 and a beta of 1.20. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.77 and a 1-year high of $10.67. The business has a 50-day moving average of $7.98 and a 200-day moving average of $8.12.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, insider Greg Keenan sold 8,305 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $8.23, for a total transaction of $68,350.15. Following the sale, the insider now directly owns 153,484 shares of the company's stock, valued at approximately $1,263,173.32. This represents a 5.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Matthew Maxwell Donley sold 65,902 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $527,216.00. Following the sale, the chief operating officer now directly owns 739,456 shares of the company's stock, valued at approximately $5,915,648. This represents a 8.18 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 343,898 shares of company stock worth $2,753,094. Corporate insiders own 4.30% of the company's stock.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.